Welcome to our dedicated page for Acumen Pharmaceuticals SEC filings (Ticker: ABOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer. Acumen files periodic reports and current reports with the U.S. Securities and Exchange Commission, including Forms 10‑K, 10‑Q and 8‑K, in connection with its development of sabirnetug (ACU193), a humanized monoclonal antibody targeting toxic soluble amyloid beta oligomers (AβOs) for the treatment of early Alzheimer’s disease.
Through its 8‑K filings, Acumen reports material events such as quarterly financial results, business highlights, strategic collaboration agreements and changes in its Board of Directors. For example, recent 8‑Ks have covered the company’s financial condition, the posting of updated corporate presentations, and the appointment of a new chairman of the board. These filings complement press releases that discuss the progress of the Phase 2 ALTITUDE-AD trial, the Enhanced Brain Delivery (EBD™) collaboration with JCR Pharmaceuticals, and other corporate developments.
On this page, users can also track how Acumen describes its status as an emerging growth company, its listing of common stock on The Nasdaq Global Select Market under the symbol ABOS, and its use of collaborations and option agreements to support development of AβO-targeted therapies. While detailed insider trading information would appear in Form 4 filings and executive compensation in proxy materials, this hub focuses on the full range of EDGAR-reported documents.
Stock Titan enhances these filings with AI-powered summaries that explain key points, highlight important sections in lengthy reports such as annual reports on Form 10‑K and quarterly reports on Form 10‑Q, and help readers quickly understand how new disclosures relate to Acumen’s Alzheimer’s disease programs and financial position.
Acumen Pharmaceuticals insider files to sell additional shares under Rule 144. A holder plans to sell 9,346 shares of Acumen Pharmaceuticals common stock through Merrill Lynch on or about 01/21/2026, with an aggregate market value of 16,927.34. The company’s common stock is listed on NASDAQ, and 60,573,425 shares were reported as outstanding.
The shares to be sold were acquired on 01/17/2026 through the vesting of a restricted stock unit award granted as part of the issuer’s equity compensation plan. The notice also lists prior sales over the past three months by Daniel O’Connell, including multiple common stock transactions in early January 2026 with individual sale amounts ranging from 4,649 to 37,755 shares and corresponding gross proceeds disclosed for each date.
Acumen Pharmaceuticals CFO & Chief Business Officer Matt Zuga reported a small insider sale of company common stock. On January 8, 2026, he sold 6,888 shares at a weighted average price of $1.8166 per share, with individual trades executed between $1.72 and $1.95.
According to the disclosure, these shares were sold through an automatic “sell to cover” transaction to satisfy tax withholding obligations triggered by the vesting of restricted stock units. The transaction was made under a Rule 10b5-1 trading plan adopted on June 30, 2025. After this activity, Zuga beneficially owned 209,951 shares of Acumen Pharmaceuticals common stock.
Acumen Pharmaceuticals, Inc. reported an insider stock sale by its Chief Operating Officer, Barton Russell. On January 8, 2026, he sold 3,530 shares of common stock in a transaction coded as a sale. The filing explains this was an automatic “sell to cover” to satisfy tax withholding obligations tied to the vesting of restricted stock units under a Rule 10b5-1 trading plan he adopted on June 25, 2025. The shares were sold at a weighted average price of $1.8588 per share, in multiple trades between $1.8000 and $1.9500. After this transaction, he continued to beneficially own 123,269 shares, all held directly.
Acumen Pharmaceuticals Chief Legal Officer Derek Meisner reported several sales of Acumen common stock under a pre-arranged Rule 10b5-1 trading plan. On January 8, 2026, he sold 6,819 shares at a weighted average price of $1.8154 in an automatic “sell to cover” transaction to satisfy tax withholding on vesting restricted stock units, and 30,092 shares at a weighted average price of $1.8233 under the same plan.
He later sold 5,200 shares on January 9, 2026 at a weighted average price of $1.7633, and 8,548 shares on January 12, 2026 at a weighted average price of $1.7148. After these transactions, Meisner directly held 83,800 shares of Acumen common stock.
Acumen Pharmaceuticals Chief Executive Officer and director Daniel Joseph O’Connell reported automatic share sales tied to tax withholding. On January 8, 9 and 12, 2026, he sold 8,143, 12,941 and 5,388 shares of Acumen Pharmaceuticals common stock, respectively, at weighted average prices of $1.8194, $1.7643 and $1.7273 per share.
According to the footnotes, these transactions represent automatic “sell to cover” trades to satisfy tax withholding obligations upon vesting of restricted stock units, pursuant to a Rule 10b5-1 trading plan adopted on June 27, 2025. After these sales, O’Connell beneficially owned 593,510 shares of common stock directly.
Acumen Pharmaceuticals, Inc. insider Derek Meisner filed a notice of proposed sale of company common stock under Rule 144. The filing covers 8,548 shares of common stock to be sold through Merrill Lynch, with an aggregate market value of $14,658.02, based on an outstanding share count of 60,573,425 shares and an approximate sale date of 01/12/2026 on the NASDAQ.
The 8,548 shares to be sold were acquired on 01/06/2026 through the vesting of a restricted stock unit award granted as part of the issuer’s equity compensation plan. The notice also lists prior sales by Meisner over the past three months, including 4,000 shares on 01/05/2026 for gross proceeds of $7,838.00 and 36,911 shares on 01/08/2026 for gross proceeds of $67,244.23, among other transactions.
Acumen Pharmaceuticals insider Daniel OConnell filed a notice of proposed sale of company common stock under Rule 144. The filing covers 5,388 shares of common stock to be sold through Merrill Lynch on the NASDAQ, with an approximate sale date of 01/12/2026 and an aggregate market value of $9,306.56 based on the form data. These shares were acquired on 01/07/2026 through the vesting of a restricted stock unit award granted as part of the issuer’s equity compensation plan.
The notice also lists recent sales of Acumen common stock by OConnell over the prior days in January 2026, including 4,649 shares on 01/05/2026 for gross proceeds of $9,163.33 and 37,755 shares on 01/07/2026 for gross proceeds of $74,980.95. By signing, the seller represents that they are not aware of any undisclosed material adverse information about Acumen’s current or prospective operations.
Acumen Pharmaceuticals, Inc. filed a current report to highlight that it has posted an updated corporate presentation on its investor website. The presentation now includes nonclinical murine brain exposure data supporting its Enhanced Brain Delivery (EBD™) program that was presented at the 2025 Clinical Trials on Alzheimer’s Disease conference, updated views of previously presented fluid biomarker data from its Phase 1 INTERCEPT-AD study, and the addition of ACU234 to the company’s pipeline in connection with the EBD program. The presentation is furnished as Exhibit 99.1 and, along with this disclosure, is designated as furnished rather than filed under securities law.
Acumen Pharmaceuticals officer James J. Doherty reported automatic sales of company stock to cover taxes tied to restricted stock unit vesting. On January 7, 2026, he sold 1,700 shares of common stock at a weighted average price of $1.9879, and on January 8, 2026 he sold 6,467 shares at a weighted average price of $1.8198, in each case through a Rule 10b5-1 trading plan.
The filing states that these were “sell to cover” transactions to satisfy tax withholding obligations and that Doherty held 54,033 shares of common stock directly after the second sale. It also notes that the reported beneficial ownership reflects a correction of a typographical error in a prior Form 4 that had overreported an RSU grant to Doherty by 400 shares.
Acumen Pharmaceuticals' Chief Regulatory Officer, Amy Schacterle, reported an automatic sale of company stock tied to tax withholding. On 01/07/2026, she sold 1,097 shares of Acumen common stock at a weighted average price of $1.9838 per share. The shares were sold under a pre-arranged Rule 10b5-1 trading plan and were executed as a “sell to cover” transaction to satisfy tax withholding obligations from the vesting of restricted stock units.
After this transaction, Schacterle beneficially owns 7,703 shares of Acumen common stock. A Rule 10b5-1 plan allows insiders to schedule trades in advance, which can help separate routine tax-related or liquidity transactions from discretionary trading decisions.